Transce3nd’s Telomir Pharmaceuticals TELO Stock Holding History

Transce3nd’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-28,803	Closed	-$119K	–	1620
2024 Q4	$119K	Buy	+28,803	New	+$136K	0.04%	231

Other funds holding TELO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SEM

Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Transce3nd's TELO Position: Q1 2025 in Review

Transce3nd sold out of Telomir Pharmaceuticals (TELO) in Q1 2025, closing a stake of 28,803 shares — an estimated $119K sold.

Transce3nd first reported a position in TELO in Q4 2024 and held it in 1 quarter. The position peaked at $119K in Q4 2024. 42 funds tracked by Wall St. Rank hold TELO as of Q1 2025.

Transce3nd reported no remaining Telomir Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Transce3nd sold 28,803 Telomir Pharmaceuticals shares in Q1 2025, an estimated $119K.
Transce3nd first reported a position in Telomir Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Transce3nd's Telomir Pharmaceuticals position peaked at $119K in Q4 2024.
42 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2025.

Based on Transce3nd's 13F filing for Q1 2025, filed 5 May 2025.